Trial Profile

A First in Human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of IBC-Ab002 in Persons With Early Alzheimer's Disease (AD)

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 27 Mar 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

19 Mar 2026 According to an ImmunoBrain Checkpoint media release, data from this trial were presented at the Alzheimer's & Parkinson's Diseases Conference (AD/PD) 2026.
12 Mar 2026 According to an ImmunoBrain Checkpoint media release, data from this trial will be presented at the oral presentation at the 2026 Alzheimer's and Parkinson's Diseases Conference (AD/PD) taking place March 17-21, 2026, in Copenhagen, Denmark.The presentation will include safety, tolerability and biomarker data in the first 40 patients dosed across four intravenous infusions of IBC-Ab002 or placebo across five escalating dose cohorts.
24 Dec 2025 Status changed from active, no longer recruiting to completed.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com